Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Finding the Universe of Workmanship: Individual Encounters in Imagination - 2World's oldest known tortoise still very much alive despite rumor to the contrary
- 3Change Your Physical make-up: Compelling Activities for Muscle Building
- 4Here are 10 stores where you can get a free Thanksgiving turkey
- 5America's Confided in Fridge in 2024
- Israeli strike on Gaza City vehicle kills at least four, report says
- ‘Harry Potter and the Philosopher’s Stone’ trailer is raising eyebrows among Potterheads: ‘Where’s the whimsical color?’
- Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life
- How to get rid of your Christmas tree — and the 1 thing to never, ever do with it
- They relied on marijuana to get through the day. But then days felt impossible without it
- Crime boss Steven Lyons set to be deported from Bali to Spain
- Discovering a sense of harmony: Individual Accounts of Reflection and Care
- What to know about the hepatitis B shot — and why Trump officials are targeting it
- Etymological Experiences on the Wireless transmissions: A Survey of \Learning in a hurry\ Language Web recording
